ANABAnaptysBio, Inc.
Price
+231%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, nothing alarming, undemanding price, growth steady, the market undecided.
We are a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Our clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which we completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (“RA”), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (“CeD”) and eosinophilic esophagitis (“EoE”), and ANB101, a BDCA2 modulator, in a Phase 1a trial.
In the company’s own words · 10-K filed Mar 3, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
AnaptysBio, Inc. (ANAB) reported revenue of $27M in Q2 2026 (quarter ended Jun 30, 2026), up 23% from the same quarter a year earlier. That came with net income of $184M (669% of revenue). For the full year FY2025, revenue was $235M (+157% year on year) and net income −$13M. Its largest product in Q3 2025 (quarter ended Sep 30, 2025) was Anaptys Bio Generated Anti PD1 Jemperli Dostarlimab at $50M, 100% of the disclosed total, well ahead of Transaction Service at 0.2%.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 21, 2026Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update.Material event (exhibits only) · press release
- Jun 22, 2026On June 15, 2026, AnaptysBio, Inc. (the “Company”), entered into a Sublease Agreement (the “Sublease”) with First Tracks Biotherapeutics, Inc., a Delaware corporation (“First Tracks”), pursuant to which the Company agreed to sublease to First Tracks approximately 45,057 rentable square feet of space located at 10770 …Material agreement entered · Form 8-K
- May 21, 2026On May 18, 2026, the Board of Directors of AnaptysBio, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from December 31 to June.Charter/bylaw amendment or fiscal-year change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q3 2025 · $50.1MThe company’s own SEC segment disclosure.
- Anaptys Bio Generated Anti PD1 Jemperli Dostarlimab$50.0M100%
- Transaction Service$100.0K0%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.